These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 9458330)
1. Abnormal transcripts of FHIT gene in thyroid cancer. Chang TJ; Tsai TC; Wu YL; Yang HM; Chi CW; Yang AH; Lee CH Oncol Rep; 1998; 5(1):245-7. PubMed ID: 9458330 [TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880 [TBL] [Abstract][Full Text] [Related]
3. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101 [TBL] [Abstract][Full Text] [Related]
4. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423 [TBL] [Abstract][Full Text] [Related]
5. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma. Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242 [TBL] [Abstract][Full Text] [Related]
6. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma. Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140 [TBL] [Abstract][Full Text] [Related]
7. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888 [TBL] [Abstract][Full Text] [Related]
8. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Simon B; Bartsch D; Barth P; Prasnikar N; Münch K; Blum A; Arnold R; Göke B Cancer Res; 1998 Apr; 58(8):1583-7. PubMed ID: 9563464 [TBL] [Abstract][Full Text] [Related]
9. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816 [TBL] [Abstract][Full Text] [Related]
10. Alterations of the FHIT gene in human hepatocellular carcinoma. Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123 [TBL] [Abstract][Full Text] [Related]
11. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas. Bugert P; Wilhelm M; Kovacs G Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948 [TBL] [Abstract][Full Text] [Related]
12. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528 [TBL] [Abstract][Full Text] [Related]
13. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines. Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495 [TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the FHIT gene in human prostate cancer. Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683 [TBL] [Abstract][Full Text] [Related]
15. [FHIT gene is abnormal in Chinese lung cancers]. Zhang J; Fu W; Zhang X Zhonghua Yi Xue Za Zhi; 1999 Aug; 79(8):592-5. PubMed ID: 11715406 [TBL] [Abstract][Full Text] [Related]
16. Loss of FHIT expression in gastric carcinoma. Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Yanagisawa K; Kondo M; Osada H; Uchida K; Takagi K; Masuda A; Takahashi T; Takahashi T Cancer Res; 1996 Dec; 56(24):5579-82. PubMed ID: 8971157 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck. Kisielewski AE; Xiao GH; Liu SC; Klein-Szanto AJ; Novara M; Sina J; Bleicher K; Yeung RS; Goodrow TL Oncogene; 1998 Jul; 17(1):83-91. PubMed ID: 9671317 [TBL] [Abstract][Full Text] [Related]
20. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma. Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]